Oral anticoagulant drugs and the risk of osteoporosis: New anticoagulants better than old?

Seminars in Thrombosis and Hemostasis

Volumn 41, Issue 4, 2015, Pages 382-388

  Tufano, Antonella ^a   Coppola, Antonio ^a   Contaldi, Paola ^a   Franchini, Massimo ^b   Minno, Giovanni Di ^a  

^a FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^b CARLO POMA HOSPITAL   (Italy)

Author keywords

fractures; oral anticoagulant drugs; osteoporosis; side effects; warfarin

Indexed keywords

4 CARBOXYGLUTAMIC ACID; ACENOCOUMAROL; ANTICOAGULANT AGENT; ANTIVITAMIN K; FLUINDIONE; GLUTAMIC ACID; PHENPROCOUMON; WARFARIN; VITAMIN K GROUP;

ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; BONE INJURY; BONE METABOLISM; BONE TURNOVER; CARBOXYLATION; DIET RESTRICTION; FRACTURE; FRAGILITY FRACTURE; HUMAN; NONHUMAN; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RIB FRACTURE; RISK ASSESSMENT; SPINE FRACTURE; VENOUS THROMBOEMBOLISM; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG EFFECTS; METABOLISM; ORAL DRUG ADMINISTRATION; PROTEIN PROCESSING;

1-CARBOXYGLUTAMIC ACID; ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; HUMANS; OSTEOPOROSIS; PROTEIN PROCESSING, POST-TRANSLATIONAL; VITAMIN K;

EID: 84931264825     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0034-1543999     Document Type: Article

References (34)

1. WHO Study Group Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser: 1994; 843 1 129
2. Czerwiński E., Badurski J. E., Marcinowska-Suchowierska E., Osieleniec J. Current understanding of osteoporosis according to the position of the World Health Organization (WHO) and International Osteoporosis Foundation. Ortop Traumatol Rehabil: 2007; 9 4 337 356
3. Mazziotti G., Canalis E., Giustina A. Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med: 2010; 123 10 877 884
4. Garcia D. A., Baglin T. P., Weitz J. I., Samama M. M. American College of Chest Physicians. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest: 2012; 141 (2, Suppl): e24S e43S
5. Casele H. L., Laifer S. A. Prospective evaluation of bone density in pregnant women receiving the low molecular weight heparin enoxaparin sodium. J Matern Fetal Med: 2000; 9 2 122 125
6. Pettilä V., Leinonen P., Markkola A., Hiilesmaa V., Kaaja R. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost: 2002; 87 2 182 186
7. Rajgopal R., Bear M., Butcher M. K., Shaughnessy S. G. The effects of heparin and low molecular weight heparins on bone. Thromb Res: 2008; 122 3 293 298
8. Lefkou E., Khamashta M., Hampson G., Hunt B. J. Review: Low-molecular-weight heparin-induced osteoporosis and osteoporotic fractures: a myth or an existing entity? Lupus: 2010; 19 1 3 12
9. Irie A., Takami M., Kubo H., Sekino-Suzuki N., Kasahara K., Sanai Y. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. Bone: 2007; 41 2 165 174
10. Ageno W., Gallus A. S., Wittkowsky A., Crowther M., Hylek E. M., Palareti G. American College of Chest Physicians. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest: 2012; 141 (2, Suppl): e44S e88S
11. Price P. A., Williamson M. K. Effects of warfarin on bone. Studies on the vitamin K-dependent protein of rat bone. J Biol Chem: 1981; 256 24 12754 12759
12. Jamal S. A., Browner W. S., Bauer D. C., Cummings S. R. Study of Osteoporotic Fractures Research Group. Warfarin use and risk for osteoporosis in elderly women. Ann Intern Med: 1998; 128 10 829 832
13. Ferrière K., Rizzoli R. Anticoagulants and osteoporosis [in French]. Rev Med Suisse: 2007; 3 115 1508 1511
14. Pearson D. A. Bone health and osteoporosis: the role of vitamin K and potential antagonism by anticoagulants. Nutr Clin Pract: 2007; 22 5 517 544
15. Vermeer C. Vitamin K: the effect on health beyond coagulation - an overview. Food Nutr Res: 2012; 56 5329
16. Prydz H. Vitamin K-dependent clotting factors. Semin Thromb Hemost: 1977; 4 1 1 14
17. Cranenburg E. C., Schurgers L. J., Vermeer C. Vitamin K: the coagulation vitamin that became omnipotent. Thromb Haemost: 2007; 98 1 120 125
18. Szulc P., Arlot M., Chapuy M. C., Duboeuf F., Meunier P. J., Delmas P. D. Serum undercarboxylated osteocalcin correlates with hip bone mineral density in elderly women. J Bone Miner Res: 1994; 9 10 1591 1595
19. Sato Y., Honda Y., Kunoh H., Oizumi K. Long-term oral anticoagulation reduces bone mass in patients with previous hemispheric infarction and nonrheumatic atrial fibrillation. Stroke: 1997; 28 12 2390 2394
20. Caraballo P. J., Heit J. A., Atkinson E. J., et al. Long-term use of oral anticoagulants and the risk of fracture. Arch Intern Med: 1999; 159 15 1750 1756
21. Caraballo P. J., Gabriel S. E., Castro M. R., Atkinson E. J., Melton L. J. III. Changes in bone density after exposure to oral anticoagulants: a meta-analysis. Osteoporos Int: 1999; 9 5 441 448
22. Pilon D., Castilloux A-M, Dorais M., LeLorier J. Oral anticoagulants and the risk of osteoporotic fractures among elderly. Pharmacoepidemiol Drug Saf: 2004; 13 5 289 294
23. Pluskiewicz W. Re: Oral anticoagulants and the risk of osteoporotic fractures among elderly. Pharmacoepidemiol Drug Saf: 2007; 16 2 238
24. Gage B. F., Birman-Deych E., Radford M. J., Nilasena D. S., Binder E. F. Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2. Arch Intern Med: 2006; 166 2 241 246
25. Woo C., Chang L. L., Ewing S. K., Bauer D. C. Osteoporotic Fractures in Men Study Group. Single-point assessment of warfarin use and risk of osteoporosis in elderly men. J Am Geriatr Soc: 2008; 56 7 1171 1176
26. Avgeri M., Papadopoulou A., Platokouki H., et al. Assessment of bone mineral density and markers of bone turnover in children under long-term oral anticoagulant therapy. J Pediatr Hematol Oncol: 2008; 30 8 592 597
27. Rezaieyazdi Z., Falsoleiman H., Khajehdaluee M., Saghafi M., Mokhtari-Amirmajdi E. Reduced bone density in patients on long-term warfarin. Int J Rheum Dis: 2009; 12 2 130 135
28. Jie K. S., Hamulyák K., Gijsbers B. L., Roumen F. J., Vermeer C. Serum osteocalcin as a marker for vitamin K-status in pregnant women and their newborn babies. Thromb Haemost: 1992; 68 4 388 391
29. Audran M. Iatrogenic demineralizing osteopathies [in French]. Presse Med: 1994; 23 6 271 273
30. Misra D., Berry S. D., Broe K. E., et al. Does dietary protein reduce hip fracture risk in elders? The Framingham Osteoporosis Study. Osteoporos Int: 2011; 22 1 345 349
31. Gigi R., Salai M., Dolkart O., et al. The effects of direct factor Xa inhibitor (Rivaroxaban) on the human osteoblastic cell line SaOS2. Connect Tissue Res: 2012; 53 6 446 450
32. Somjen D., Katzburg S., Gigi R., et al. Rivaroxaban, a direct inhibitor of the coagulation factor Xa interferes with hormonal-induced physiological modulations in human female osteoblastic cell line SaSO2. J Steroid Biochem Mol Biol: 2013; 135 67 70
33. Winkler T., Perka C., Matziolis D., Matziolis G. Effect of a direct thrombin inhibitor compared with dalteparin and unfractionated heparin on human osteoblasts. Open Orthop J: 2011; 5 52 58
34. Morishima Y., Kamisato C., Honda Y., Furugohri T., Shibano T. The effects of warfarin and edoxaban, an oral direct factor Xa inhibitor, on gammacarboxylated (Gla-osteocalcin) and undercarboxylated osteocalcin (uc-osteocalcin) in rats. Thromb Res: 2013; 131 1 59 63